Loading clinical trials...

BOTOX® in the Treatment of Upper Facial Lines in Japan | Clinical Trials | Clareo Health

COMPLETEDPHASE3

BOTOX® in the Treatment of Upper Facial Lines in Japan

NCT01797094•Allergan

Summary

This study will evaluate the safety and efficacy of BOTOX® (botulinum toxin Type A) for the treatment of upper facial lines (Crow's Feet Lines and Frown Lines).

Eligibility

Age

20 - 64 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Moderate to severe Crow's Feet Lines and Frown Lines

Exclusion Criteria

•Current or previous botulinum toxin treatment of any serotype
•Diagnosis of Myasthenia gravis, Eaton-Lambert Syndrome, Amyotrophic Lateral Sclerosis
•Facial laser or light treatment for cosmetic purposes, microdermabrasion, superficial peels, or topical retinoid therapy or hormone cream within 3 months
•Laser treatment or phototherapy of the face for medical purposes, blepharoplasty, brow-lift or related procedure, periorbital permanent make-up, or oral retinoid therapy within one year
•Medium-depth or deep facial peels within 5 years
•Prior facial cosmetic surgery (e.g., prior periorbital surgery, facial lift, periorbital treatment with fillers, implantation or transplantation)

Locations (1)

Tokyo, Japan

Key Dates

Start Date

February 1, 2013

Primary Completion Date

July 1, 2013

Completion Date

July 1, 2014

Last Updated

February 10, 2015

Enrollment

101

ACTUAL participants

Conditions

Upper Facial RhytidesCrow's Feet LinesGlabellar LinesFrown Lines

Interventions

botulinum toxin Type A (44U)

BIOLOGICAL

botulinum toxin Type A (32U)

BIOLOGICAL

A Study to Investigate the Safety and Efficacy of YY003 in Adults with Moderate to Severe Glabellar Lines

NCT06481475

Moderate to Severe Glabellar Lines

View study

ACTIVE_NOT_RECRUITINGPHASE2

A Study to Evaluate AI-09 In Participants With Glabellar Lines

NCT07321834

Glabellar Lines

View study

ACTIVE_NOT_RECRUITINGPHASE3

A Study on the Efficacy and Safety of Repeated Treatments With Recombinant Botulinum Toxin Type A for Injection in the Treatment of Moderate to Severe Glabellar Lines

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 10, 2015Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

BOTOX® in the Treatment of Upper Facial Lines in Japan

Inclusion Criteria

Exclusion Criteria

A Study to Investigate the Safety and Efficacy of YY003 in Adults with Moderate to Severe Glabellar Lines

A Study to Evaluate AI-09 In Participants With Glabellar Lines

A Study on the Efficacy and Safety of Repeated Treatments With Recombinant Botulinum Toxin Type A for Injection in the Treatment of Moderate to Severe Glabellar Lines

Clinical Trial to Evaluate the Safety and Efficacy of JTM201 to Treat Moderate or Severe Glabellar Lines

Non-interventional Study, Long Term Treatment on Glabellar Lines With Dysport® in Subjects of Chinese Origin

A Study Comparing DMSB01 and Rejuran® for Temporary Crow's Feet Lines Improvement